Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has reaffirmed a Buy rating on Cyclacel Pharmaceuticals (NASDAQ:CYCC) and increased the price target from $16 to $21.
December 19, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Jonathan Aschoff maintains a Buy rating on Cyclacel Pharmaceuticals and raises the price target from $16 to $21.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, which can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100